| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,159,607 ) |
| | 2024 | 2024 | FUNDACAO OSWALDO CRUZ | AVENIDA BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 17 | NIH | 10/27/2023 | $444,821 |
| | 2024 | 2024 | FUNDACAO OSWALDO CRUZ | AVENIDA BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 17 | NIH | 10/27/2023 | $158,941 |
| | 2024 | 2024 | FUNDACAO OSWALDO CRUZ | AVENIDA BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | R01AI183314 | An extracellular vesicle component as a candidate to control cryptococcosis. | 000 | 1 | NIH | 3/21/2024 | $115,880 |
| | 2024 | 2024 | FUNDACAO OSWALDO CRUZ | AVENIDA BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | R01MH128911 | The impact of social drivers, conditional cash transfers and their mechanisms on mental health of the young: an integrated retrospective and forecasting approach using the 100 million Brazilian Cohort | 000 | 3 | NIH | 10/20/2023 | $344,334 |
| | 2024 | 2024 | FUNDACAO OSWALDO CRUZ | AVENIDA BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 17 | NIH | 10/27/2023 | $95,631 |
|
| Issue Date FY: 2023 ( Subtotal = $1,892,931 ) |
| | 2023 | 2023 | FUNDACAO OSWALDO CRUZ | AV BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 16 | NIH | 11/16/2022 | $198,743 |
| | 2023 | 2023 | FUNDACAO OSWALDO CRUZ | AV BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | R01MH128911 | The impact of social drivers, conditional cash transfers and their mechanisms on mental health of the young: an integrated retrospective and forecasting approach using the 100 million Brazilian Cohort | 000 | 2 | NIH | 11/10/2022 | $328,130 |
| | 2023 | 2023 | FUNDACAO OSWALDO CRUZ | AV BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 16 | NIH | 11/16/2022 | $517,239 |
| | 2023 | 2023 | FUNDACAO OSWALDO CRUZ | AV BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | R01MH128911 | The impact of social drivers, conditional cash transfers and their mechanisms on mental health of the young: an integrated retrospective and forecasting approach using the 100 million Brazilian Cohort | 001 | 2 | NIH | 1/20/2023 | $36,457 |
| | 2023 | 2023 | FUNDACAO OSWALDO CRUZ | AV BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 16 | NIH | 5/25/2023 | $198,742 |
| | 2023 | 2023 | FUNDACAO OSWALDO CRUZ | AV BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 16 | NIH | 5/25/2023 | $570,900 |
| | 2023 | 2023 | FUNDACAO OSWALDO CRUZ | AV BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 16 | NIH | 11/16/2022 | $21,360 |
| | 2023 | 2023 | FUNDACAO OSWALDO CRUZ | AV BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 16 | NIH | 5/25/2023 | $21,360 |
| | 2023 | 2021 | FUNDACAO OSWALDO CRUZ | AVENIDA BRASIL 4365 QUININO, SALA 303 | RIO DE JANEIRO | | | | BRA | R01AI129835 | The role of Tregs and lipid mediators in the progression of Mycobacterium leprae infection to active disease | 000 | 5 | NIH | 7/12/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,091,253 ) |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 15 | NIH | 11/22/2021 | $304,432 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 15 | NIH | 7/21/2022 | $53,318 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 15 | NIH | 11/22/2021 | $696,498 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 15 | NIH | 11/22/2021 | $83,395 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 15 | NIH | 7/21/2022 | $415,063 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | R01MH128911 | The impact of social drivers, conditional cash transfers and their mechanisms on mental health of the young: an integrated retrospective and forecasting approach using the 100 million Brazilian Cohort | 000 | 1 | NIH | 12/9/2021 | $343,910 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | R01MH128911 | The impact of social drivers, conditional cash transfers and their mechanisms on mental health of the young: an integrated retrospective and forecasting approach using the 100 million Brazilian Cohort | 002 | 1 | NIH | 4/25/2022 | $343,910 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | R01MH128911 | The impact of social drivers, conditional cash transfers and their mechanisms on mental health of the young: an integrated retrospective and forecasting approach using the 100 million Brazilian Cohort | 001 | 1 | NIH | 4/21/2022 | -$343,910 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 002 | 15 | NIH | 7/26/2022 | $0 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 002 | 15 | NIH | 7/26/2022 | $0 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 002 | 15 | NIH | 7/26/2022 | $0 |
| | 2022 | 2022 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 15 | NIH | 7/21/2022 | $194,637 |
|
| Issue Date FY: 2021 ( Subtotal = $2,934,618 ) |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 003 | 14 | NIH | 9/10/2021 | $0 |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 14 | NIH | 11/20/2020 | $77,075 |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 14 | NIH | 11/20/2020 | $570,900 |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 14 | NIH | 11/20/2020 | $747,481 |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 002 | 14 | NIH | 9/1/2021 | $77,075 |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 002 | 14 | NIH | 9/1/2021 | $570,900 |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 002 | 14 | NIH | 9/1/2021 | $747,481 |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 003 | 14 | NIH | 9/10/2021 | $0 |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 003 | 14 | NIH | 9/10/2021 | $0 |
| | 2021 | 2021 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | R01AI129835 | The role of Tregs and lipid mediators in the progression of Mycobacterium leprae infection to active disease | 000 | 5 | NIH | 8/31/2021 | $143,706 |
| | 2021 | 2020 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 13 | NIH | 8/10/2021 | $0 |
| | 2021 | 2019 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | | | BRA | R21AI139777 | Study on the persistence of Zika virus (ZIKV) in body fluids of patients with ZIKV infection in Brazil | 000 | 2 | NIH | 11/10/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,150,517 ) |
| | 2020 | 2020 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | 21040-360 | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 13 | NIH | 5/20/2020 | $386,799 |
| | 2020 | 2020 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | 21040-360 | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 13 | NIH | 5/20/2020 | $6,570 |
| | 2020 | 2020 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | 21040-360 | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 13 | NIH | 11/20/2019 | $610,026 |
| | 2020 | 2020 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | 21040-360 | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 13 | NIH | 11/20/2019 | $386,802 |
| | 2020 | 2020 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | 21040-360 | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 000 | 13 | NIH | 11/20/2019 | $6,571 |
| | 2020 | 2020 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | 21040-360 | | BRA | UM1AI069476 | The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | 001 | 13 | NIH | 5/20/2020 | $610,026 |
| | 2020 | 2020 | FUNDACAO OSWALDO CRUZ. | AV. BRASIL 4.365, C. DE REL. INTE. EM SAUDE | RIO DE JANEIRO | RJ | 21040-360 | | BRA | R01AI129835 | The role of Tregs and lipid mediators in the progression of Mycobacterium leprae infection to active disease | 000 | 4 | NIH | 3/17/2020 | $143,723 |
|
|
